231 related articles for article (PubMed ID: 29672754)
1. Comorbidity clusters in people with gout: an observational cohort study with linked medical record review.
Bevis M; Blagojevic-Bucknall M; Mallen C; Hider S; Roddy E
Rheumatology (Oxford); 2018 Aug; 57(8):1358-1363. PubMed ID: 29672754
[TBL] [Abstract][Full Text] [Related]
2. Onset of comorbidities and flare patterns within pre-existing morbidity clusters in people with gout: 5-year primary care cohort study.
Bajpai R; Muller S; Mallen C; Watson L; Richette P; Hider SL; Roddy E
Rheumatology (Oxford); 2021 Dec; 61(1):407-412. PubMed ID: 33744931
[TBL] [Abstract][Full Text] [Related]
3. Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
Sandoval-Plata G; Nakafero G; Chakravorty M; Morgan K; Abhishek A
Rheumatology (Oxford); 2021 Jul; 60(7):3243-3251. PubMed ID: 33313843
[TBL] [Abstract][Full Text] [Related]
4. Revisiting comorbidities in gout: a cluster analysis.
Richette P; Clerson P; Périssin L; Flipo RM; Bardin T
Ann Rheum Dis; 2015 Jan; 74(1):142-7. PubMed ID: 24107981
[TBL] [Abstract][Full Text] [Related]
5. The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factors-30 years follow-up of the Malmö Preventive Project.
Fatima T; Nilsson PM; Turesson C; Dehlin M; Dalbeth N; Jacobsson LTH; Kapetanovic MC
Arthritis Res Ther; 2020 Oct; 22(1):244. PubMed ID: 33066806
[TBL] [Abstract][Full Text] [Related]
6. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.
Bardin T; Richette P
BMC Med; 2017 Jul; 15(1):123. PubMed ID: 28669352
[TBL] [Abstract][Full Text] [Related]
7. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
8. Comorbidities in gout and hyperuricemia: causality or epiphenomena?
Sumpter NA; Saag KG; Reynolds RJ; Merriman TR
Curr Opin Rheumatol; 2020 Mar; 32(2):126-133. PubMed ID: 31876630
[TBL] [Abstract][Full Text] [Related]
9. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
10. Burden and management of gout in a multi-ethnic Asian cohort.
Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
[TBL] [Abstract][Full Text] [Related]
11. Clustering of gout-related comorbidities and their relationship with gout flares: a data-driven cluster analysis of eight comorbidities.
Liu S; Sun H; Yang S; Liang N; Gao Y; Qu S; Chen H
J Endocrinol Invest; 2024 May; 47(5):1119-1128. PubMed ID: 37906371
[TBL] [Abstract][Full Text] [Related]
12. Gout characteristics associate with depression, but not anxiety, in primary care: Baseline findings from a prospective cohort study.
Prior JA; Mallen CD; Chandratre P; Muller S; Richardson J; Roddy E
Joint Bone Spine; 2016 Oct; 83(5):553-8. PubMed ID: 27068619
[TBL] [Abstract][Full Text] [Related]
13. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
[TBL] [Abstract][Full Text] [Related]
14. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population.
Singh JA; Cleveland JD
BMC Nephrol; 2019 Mar; 20(1):93. PubMed ID: 30876398
[TBL] [Abstract][Full Text] [Related]
15. Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis.
Nyberg F; Horne L; Morlock R; Nuevo J; Storgard C; Aiyer L; Hines DM; Ansolabehere X; Chevalier P
Adv Ther; 2016 Jul; 33(7):1180-98. PubMed ID: 27230988
[TBL] [Abstract][Full Text] [Related]
16. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study.
Fraser SD; Roderick PJ; May CR; McIntyre N; McIntyre C; Fluck RJ; Shardlow A; Taal MW
BMC Nephrol; 2015 Dec; 16():193. PubMed ID: 26620131
[TBL] [Abstract][Full Text] [Related]
17. Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Joo K; Kwon SR; Lim MJ; Jung KH; Joo H; Park W
J Korean Med Sci; 2014 May; 29(5):657-61. PubMed ID: 24851021
[TBL] [Abstract][Full Text] [Related]
18. Comorbidities in patients with crystal diseases and hyperuricemia.
Sattui SE; Singh JA; Gaffo AL
Rheum Dis Clin North Am; 2014 May; 40(2):251-78. PubMed ID: 24703346
[TBL] [Abstract][Full Text] [Related]
19. Gout epidemiology and comorbidities.
Singh JA; Gaffo A
Semin Arthritis Rheum; 2020 Jun; 50(3S):S11-S16. PubMed ID: 32620196
[TBL] [Abstract][Full Text] [Related]
20. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study.
Stack AG; Johnson ME; Blak B; Klein A; Carpenter L; Morlock R; Maguire AR; Parsons VL
BMJ Open; 2019 Aug; 9(8):e031550. PubMed ID: 31462487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
